UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 23, 2001
Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
England and Wales
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-29630 N/A
- ----------------------------------- --------------------------------------
(Commission File Number) (IRS Employer Identification No.)
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 44 1256 894 000
------------------------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
On July 23, 2001, Shire Pharmaceuticals Group plc (the "Company") issued a
press release describing its results of operations for the second quarter of
2001 (the "Press Release"), which was subsequently corrected for a typographical
error. The corrected press release is attached hereto as Exhibit 99.1 and
incorporated by reference herein. In the section of the Press Release entitled
"Overview of Financial Results", and in the subsection entitled "Taxation", the
Company provided: "The effective rate of tax on the profits for the quarter pre
APB25 exceptionals and merger charges is 25% (Q2 2000: 29% Pre APB25 and
exceptional income)." The Q2 2000 effective rate of tax has a typographical
error and this sentence should read: "The effective rate of tax on the profits
for the quarter pre APB25 exceptionals and merger charges is 25% (Q2 2000: 22%
Pre APB25 and exceptional income)."
Item 7. Financial Statements and Exhibits
(c) Exhibits. The following exhibit is filed herewith:
99.1 A copy of the Press Release dated July 23, 2001, correcting the
typographical error described in Item 5 herein.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: July 24, 2001 SHIRE PHARMACEUTICALS GROUP PLC
By: /s/ Angus C. Russell
-----------------------------------------
Name: Angus C. Russell
Title: Group Finance Director
EXHIBIT INDEX
Number Description
99.1 A copy of the Press Release dated July 23, 2001, correcting the
typographical error described in Item 5 herein.